Regimens Reviewed or Under Review for Quality-Based Funding
The following regimens have been requested to be added to the Systemic Treatment – Quality-Based Procedure (ST-QBP) evidence-informed list.
Before requesting a new or modified regimen for funding consideration, verify whether the regimen is already under review (pending) or was previously not approved by searching this page for the regimen name.
| ST-QPB Regimen Request Status Tracker Regimen | Disease Site | Intent | Drugs Within the Regimens | Status |
|---|---|---|---|---|
| RITU(DESENS) | Hematologic | All | Rituximab given using a desensitization protocol | Approved |
| TRAS(DESENS) | Breast, Gastrointestinal | All | Trastuzumab given using a desensitization protocol | Approved |
| CISPPEME+PEMB; CRBPPEME+PEMB; PEMB(MNT) | Lung (Mesothelioma) | Palliative | Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab | Approved |
| LAZE+AMIV | Lung | Palliative | Lazertinib, Amivantamab | Approved |
| TEPO | Lung | Palliative | Tepotinib | Approved |
| ABIRPRED | Genitourinary | Adjuvant/Curative | Abiraterone, Prednisone | Approved |
| CRBPDOCE | Genitourinary | Palliative | Carboplatin, Docetaxel | Approved |
| CRBPPACL+DOST; DOST(MNT) | Gynaecologic | Adjuvant/Curative Palliative | Dostarlimab, Paclitaxel, Carboplatin, | Approved |
| CRBPPACL+DURV; DURV(MNT); OLAP+DURV(MNT) | Gynaecologic | Adjuvant/Curative Palliative | Durvalumab, Carboplatin, Paclitaxel, Olaparaib | Approved |
| BORTDEXA+BELA | Hematology | Palliative | Bortezomib, Dexamethasone, Belantamab | Approved |
| BORTDEXALENA+ISAT | Hematology | Palliative | Isatuximab, Bortezomib, Lenalidomide, Dexamethasone | Approved |
| DEXAPOMA+BELA | Hematology | Palliative | Belantamab, Pomalidomide, Dexamethasone | Approved |
| IBRU+RITU | Hematology | Palliative | Ibrutinib, Rituximab | Approved |
| TALQ | Hematology | Palliative | Talquetamab | Not Approved |
| EC+PEMB | Breast | Neoadjuvant | Epirubicin, Cyclophosphamide, Pembrolizumab | Approved |
| CRBPDOCE+PEMB | Breast | Adjuvant/Curative | Carboplatin, Docetaxel, Pembrolizumab | Approved |
| IVOS | Gastrointestinal | Palliative | Ivosidenib | Pending |
| RELU | Genitourinary | Palliative | Relugolix | Approved |
| CRBPPACL(W) | Gynaecologic | Adjuvant/Curative Palliative |
Carboplatin, Paclitaxel | Approved |
| BLIN(CONS) | Hematologic | Adjuvant/Curative Palliative |
Blinatumomab | Approved |
| CHOP+IR-DHAP+R; IBRU(MNT) | Hematologic | Palliative | Ibrutinib | Approved |
| DEXAPOMASELI | Hematologic | Palliative | Selinexor, Pomalidomide, dexamethasone | Approved |
| GEMOX+GLOF; GLOF(MNT) | Hematologic | Palliative | Obinutuzumab, Gemcitabine, Oxaliplatin, Glofitamab | Approved |
| IBRUVENE | Hematologic | Palliative | Ibrutinib, Venetoclax | Approved |
| CRBPPACL+PEMB; PEMB(MNT) | Gynecologic | Adjuvant/Curative Palliative | Carboplatin, Paclitaxel, Pembrolizumab | Approved |
| CRBPPACL(W) | Gynecologic | Adjuvant/Curative | Carboplatin, Paclitaxel | Approved |
| CISP(RT-W)+PEMB; CRBP(RT)+PEMB; PEMB | Gynecologic | Adjuvant/Curative | Pembrolizumab, Cisplatin, Carboplatin | Approved |
| AVD+NIVL | Hematologic | Adjuvant/Curative | Doxorubicin, Vinblastine, Dacarbazine, Nivolumab | Approved |
| BLIN | Hematologic | Adjuvant/Curative Palliative | Blinatumomab | Pending |
| BORTDEXALENA+DARA(SC); LENA+DARA(MNT-SC) | Hematologic | Palliative | Bortezomib, Dexamethasone, Lenalidomide, Daratumumab | Approved |
| BreCADD | Hematologic | Adjuvant/Curative | Brentuximab, Doxorubicin, Cyclophosphamide, Etoposide, Dacarbazine, Dexamethasone | Approved |
| CHP+POLA+RITU | Hematologic | Adjuvant/Curative | Cyclophosphamide, Doxorubicin, Prednisone, Polatuzumab Vedotin, Rituximab | Approved |
| GEMOX+PEG | Hematologic | Adjuvant/Curative | Pegaspargase, Gemcitabine, Oxaliplatin | Approved |
| DOXOTRBC; TRBC(MNT) | Sarcoma | Palliative | Doxorubicin, Trabectedin, Trabecetedin Mainetance | Approved |
| ABIROLAPPRED | Genitourinary | Palliative | Abiraterone, Olaparib, Prednisone/Prednisolone | Approved |
| BELZ | Gastrointestinal | Palliative | Belzutifan | Approved |
| NIVL+IPIL; NIVL(MNT) | Skin | Palliative | Nivolumab, Ipilimumab | Approved |
| CALA(DESENS) | Hematologic | Curative | Calaspargase Pegol | Approved |
| MFOLFOX6+ZOLB, XELOX+ZOLB; CAPECISP+ZOLB; CAPECRBP+ZOLB; CISPFU+ZOLB; CRBPFU+ZOLB; ZOLB(MNT); CAPE+ZOLB(MNT); FU+ZOLB(MNT) | Gastrointestinal | Palliative | Zolbituximab, Chemo backbone | Approved |